Hologic (HOLX) Stock Price & Analysis

HOLX$76.01+0.00 0.00%
Medical - Instruments & SuppliesLarge CapHigh Quality
Compare
Market cap$16.97BEnterprise value$17.32BRevenue (TTM)$4.13BMarket positionTop 25%

Score

46
Neutral
Value
42
Quality
65
Growth
32

AI Analysis

Snapshot

Hologic is a mixed profile at 46/100 — Value 42, Growth 32, Quality 65. Under the hood: P/E 30.3, rich vs its own history, plus revenue compounding ~-5% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

42
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

32
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

65
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Hologic, Inc. (HOLX) last printed $76.01. Equity value is $16.97B. Trailing earnings multiple 30.39. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$2.83B$3.06B$3.22B$3.37B$3.78B$5.63B$4.86B$4.03B$4.03B$4.1B

About

Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.

Hologic (HOLX) Stock Price & Analysis

HOLX price $76.01 +0.00 0.00%

Ticker
HOLX
Price
$76.01
Change
+0.00 0.00%
Market cap
$16.97B
P/E
30.39
Forward P/E
15.87
Dividend yield
0.00%
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Stocklytics score
46
Value
42
Quality
65
Growth
32

Stocklytics score rationale: value 42, quality 65, growth 32.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener